Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05266430 · ClinicalTrials.gov registry record
Prospective Group-Matched Study With Belzupacap Sarotalocan (Bel-sar; AU-011) or Plaque Radiotherapy for Primary Indeterminate Lesions or Choroidal Melanoma (IL/ CM)
A clinical trial, sponsored by Aura Biosciences.
- Terminated
- Registry status
- 2
- Enrollment target
NCT05266430 is a clinical trial that was terminated before completion, run by Aura Biosciences. The registered enrollment target is 2 participants.
The verdict
NCT05266430 was terminated before completion, sponsored by Aura Biosciences.
- TERMINATED
- Registry status
- 2 participants
- Enrollment target
Study Summary
This is a prospective multicenter, group-matched study of patients with primary indeterminate lesions or choroidal melanoma who receive treatment with belzupacap sarotalocan (bel-sar; AU-011) and patients who are planned to receive standard of care (SOC) treatment with plaque radiotherapy (plaque) to compare the visual outcomes of AU-011 and plaque radiotherapy.
Interventions
- OTHER Standard of Care
- DRUG AU-011
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2022-04-14 |
| Est. Completion | 2023-04-20 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05266430
The ClinicalTrials.gov registry entry for NCT05266430 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aura Biosciences, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Standard of Care is the first listed.
NCT05266430 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05266430 about?
NCT05266430 is a clinical study titled "Prospective Group-Matched Study With Belzupacap Sarotalocan (Bel-sar; AU-011) or Plaque Radiotherapy for Primary Indeterminate Lesions or Choroidal Melanoma (IL/ CM)". This is a prospective multicenter, group-matched study of patients with primary indeterminate lesions or choroidal melanoma who receive treatment with belzupacap sarotalocan (bel-sar; AU-011) and patients who are planned to receive standard of care (SOC) treatment with plaque radiotherapy (plaque) t...
What is the current status of trial NCT05266430?
This trial is currently terminated. The enrollment target is 2 participants. The study started on 2022-04-14. Estimated completion is 2023-04-20.
What interventions are being tested in trial NCT05266430?
The interventions under investigation include: Standard of Care (OTHER), AU-011 (DRUG).
Who is sponsoring clinical trial NCT05266430?
This trial is sponsored by Aura Biosciences, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.